• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
EVE
Click for more information
0.00% 0.1¢

EVE HEALTH GROUP LIMITED. - Announcements

Market Cap $5.274M  ! watchlist Created with Sketch. Add to my watchlist

EVE Health Group Limited is an Australia-based vertically integrated producer of branded... EVE Health Group Limited is an Australia-based vertically integrated producer of branded nutrition, health and wellness products. The Company’s Meluka business provides branded wellness consumer products. Its Meluka business is focused on supporting sales of its digestive health products, in particular the P3 Gut Builder. It provides probiotic supplement powder system for improved digestive health. The functional gut nutrition solution is in the form of a three-step supplement powder system, each of which contain pre, pro and postbiotics as well as selected functional superfood ingredients in an easy to consume and versatile offering. The Company also offers honey and essential oil products. Its honey products include organic raw honey and raw honey probiotic concentrate. The Company has global reach and application to various markets across Australia and New Zealand, Asia Pacific and North America.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
EVE EVE Investments Webcast on Omniblend Innovation-EVE.AX 13/10/16
EVE Extension of Omniblend Innovation Tranche 2 Settlement-EVE.AX 30/09/16
EVE New Study- GlucoControl Improves Long-Term Glycaemic Control-EVE.AX PRICE SENSITIVE21/09/16
EVE Update on Omniblend Innovation-EVE.AX 14/09/16
EVE Net Tangible Asset Backing-EVE.AX 09/09/16
EVE Appendix 4E and Full Year Statutory Accounts-EVE.AX PRICE SENSITIVE01/09/16
EVE Omniblend Innovation Enters into US Representation Deal-EVE.AX PRICE SENSITIVE24/08/16
EVE Net Tangible Asset Backing-EVE.AX 12/08/16
EVE Appendix 4C - Quarterly-EVE.AX PRICE SENSITIVE27/07/16
EVE Net Tangible Asset Backing-EVE.AX 14/07/16
EVE Omniblend Innovation Appoints Director of Sales & Marketing-EVE.AX 12/07/16
EVE GlucoControl for type 2 diabetes named Product of the Month-EVE.AX 08/07/16
EVE GlucoControl Momentum-EVE.AX PRICE SENSITIVE05/07/16
EVE Net Tangible Asset Backing-EVE.AX 10/06/16
EVE Appendix 3B and Change of Director's Interest Notice x 3-EVE.AX 31/05/16
EVE Results of Meeting-EVE.AX 31/05/16
EVE Net Tangible Asset Backing-EVE.AX 13/05/16
EVE Exclusive Engagement Signed with OHC for Scandinavia-EVE.AX 12/05/16
EVE GlucoControl Pre-Meal Drink Launched-EVE.AX PRICE SENSITIVE06/05/16
EVE Appendix 3B-EVE.AX 03/05/16
EVE Notice of General Meeting/Proxy Form-EVE.AX 29/04/16
EVE Appendix 4C - Quarterly-EVE.AX PRICE SENSITIVE26/04/16
EVE Omniblend Innovation Transaction Completed-EVE.AX 22/04/16
EVE Net Tangible Asset Backing-EVE.AX 15/04/16
EVE Change in Substantial Holding01/04/16
EVE Extension of Omniblend Innovation Tranche 2 SettlementPRICE SENSITIVE01/04/16
EVE Med-Tech Executive Joins EVE Board31/03/16
EVE Completion of $1.85M Non-Renounceable Rights Issue21/03/16
EVE Net Tangible Asset Backing04/03/16
EVE Half Yearly Report and AccountsPRICE SENSITIVE01/03/16
EVE GlucoControl Product Manufacturing CommencesPRICE SENSITIVE25/02/16
EVE Letter to Shareholders22/02/16
EVE Letter to Optionholders18/02/16
EVE Appendix 3B18/02/16
EVE ProspectusPRICE SENSITIVE18/02/16
EVE Fully Underwritten Rights IssuePRICE SENSITIVE18/02/16
EVE Net Tangible Asset Backing15/02/16
EVE Investor Presentation - Omniblend Innovation Acquisition03/02/16
EVE Shareholder Update02/02/16
EVE Appendix 4C - QuarterlyPRICE SENSITIVE29/01/16
EVE Net Tangible Asset Backing13/01/16
EVE Change in Substantial Holding12/01/16
EVE Change of Director's Interest Notice x 204/01/16
EVE Appendix 3B04/01/16
EVE Additional Information under Listing Rule 4.10.2018/12/15
EVE EVE Investments makes first medical technology investmentPRICE SENSITIVE17/12/15
EVE Trading HaltPRICE SENSITIVE15/12/15
EVE Net Tangible Asset Backing11/12/15
EVE Appendix 3B30/11/15
EVE Change of Company Name23/11/15
EVE Results of Meeting20/11/15
EVE Net Tangible Asset Backing13/11/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE20/10/15
EVE Notice of Annual General Meeting/Proxy Form19/10/15
EVE ProspectusPRICE SENSITIVE19/10/15
EVE Appendix 4G and Corporate Governance Statement19/10/15
EVE Annual Report to shareholders19/10/15
EVE Net Tangible Asset Backing15/10/15
EVE Appendix 3B and Change of Director's Interest Notice x 302/10/15
EVE Net Tangible Asset Backing14/09/15
EVE Change to AUD Presentation Currency04/09/15
EVE Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE28/08/15
EVE Net Tangible Asset Backing14/08/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE30/07/15
EVE Net Tangible Asset Backing13/07/15
EVE Change in Substantial Holding09/07/15
EVE Change of Director's Interest Notice x 307/07/15
EVE Appendix 3B07/07/15
EVE PlacementPRICE SENSITIVE29/06/15
EVE Trading HaltPRICE SENSITIVE25/06/15
EVE Company UpdatePRICE SENSITIVE24/06/15
EVE Net Tangible Asset Backing12/06/15
EVE Net Tangible Asset Backing14/05/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE27/04/15
EVE Net Tangible Asset Backing14/04/15
EVE Change in substantial holding10/04/15
EVE Change of Director's Interest Notice x 310/04/15
EVE Appendix 3B10/04/15
EVE Net Tangible Asset Backing12/03/15
EVE Half Yearly Report and AccountsPRICE SENSITIVE27/02/15
EVE Company UpdatePRICE SENSITIVE27/02/15
EVE Net Tangible Asset Backing10/02/15
EVE Appendix 4C - QuarterlyPRICE SENSITIVE28/01/15
EVE Net Tangible Asset Backing13/01/15
EVE Change of Director's Interest Notice x 313/01/15
EVE Appendix 3B13/01/15
EVE Net Tangible Asset Backing10/12/14
EVE Results of Meeting18/11/14
EVE Net Tangible Asset Backing12/11/14
EVE Appendix 4C - QuarterlyPRICE SENSITIVE30/10/14
EVE Annual Report to shareholders17/10/14
EVE Notice of General Meeting/Proxy Form17/10/14
EVE Net Tangible Asset Backing10/10/14
EVE Change of Director's Interest Notice x 301/10/14
EVE Appendix 3B01/10/14
EVE Net Tangible Asset Backing16/09/14
EVE Appendix 3B02/09/14
EVE Appendix 4E and Full Year Statutory AccountsPRICE SENSITIVE29/08/14
EVE Change of Company Address22/08/14
EVE Net Tangible Asset Backing13/08/14
EVE EVE Investments Webcast on Omniblend Innovation-EVE.AX
13/10/16
EVE Extension of Omniblend Innovation Tranche 2 Settlement-EVE.AX
30/09/16
EVE New Study- GlucoControl Improves Long-Term Glycaemic Control-EVE.AX
21/09/16PRICE SENSITIVE
EVE Update on Omniblend Innovation-EVE.AX
14/09/16
EVE Net Tangible Asset Backing-EVE.AX
09/09/16
EVE Appendix 4E and Full Year Statutory Accounts-EVE.AX
01/09/16PRICE SENSITIVE
EVE Omniblend Innovation Enters into US Representation Deal-EVE.AX
24/08/16PRICE SENSITIVE
EVE Net Tangible Asset Backing-EVE.AX
12/08/16
EVE Appendix 4C - Quarterly-EVE.AX
27/07/16PRICE SENSITIVE
EVE Net Tangible Asset Backing-EVE.AX
14/07/16
EVE Omniblend Innovation Appoints Director of Sales & Marketing-EVE.AX
12/07/16
EVE GlucoControl for type 2 diabetes named Product of the Month-EVE.AX
08/07/16
EVE GlucoControl Momentum-EVE.AX
05/07/16PRICE SENSITIVE
EVE Net Tangible Asset Backing-EVE.AX
10/06/16
EVE Appendix 3B and Change of Director's Interest Notice x 3-EVE.AX
31/05/16
EVE Results of Meeting-EVE.AX
31/05/16
EVE Net Tangible Asset Backing-EVE.AX
13/05/16
EVE Exclusive Engagement Signed with OHC for Scandinavia-EVE.AX
12/05/16
EVE GlucoControl Pre-Meal Drink Launched-EVE.AX
06/05/16PRICE SENSITIVE
EVE Appendix 3B-EVE.AX
03/05/16
EVE Notice of General Meeting/Proxy Form-EVE.AX
29/04/16
EVE Appendix 4C - Quarterly-EVE.AX
26/04/16PRICE SENSITIVE
EVE Omniblend Innovation Transaction Completed-EVE.AX
22/04/16
EVE Net Tangible Asset Backing-EVE.AX
15/04/16
EVE Change in Substantial Holding
01/04/16
EVE Extension of Omniblend Innovation Tranche 2 Settlement
01/04/16PRICE SENSITIVE
EVE Med-Tech Executive Joins EVE Board
31/03/16
EVE Completion of $1.85M Non-Renounceable Rights Issue
21/03/16
EVE Net Tangible Asset Backing
04/03/16
EVE Half Yearly Report and Accounts
01/03/16PRICE SENSITIVE
EVE GlucoControl Product Manufacturing Commences
25/02/16PRICE SENSITIVE
EVE Letter to Shareholders
22/02/16
EVE Letter to Optionholders
18/02/16
EVE Appendix 3B
18/02/16
EVE Prospectus
18/02/16PRICE SENSITIVE
EVE Fully Underwritten Rights Issue
18/02/16PRICE SENSITIVE
EVE Net Tangible Asset Backing
15/02/16
EVE Investor Presentation - Omniblend Innovation Acquisition
03/02/16
EVE Shareholder Update
02/02/16
EVE Appendix 4C - Quarterly
29/01/16PRICE SENSITIVE
EVE Net Tangible Asset Backing
13/01/16
EVE Change in Substantial Holding
12/01/16
EVE Change of Director's Interest Notice x 2
04/01/16
EVE Appendix 3B
04/01/16
EVE Additional Information under Listing Rule 4.10.20
18/12/15
EVE EVE Investments makes first medical technology investment
17/12/15PRICE SENSITIVE
EVE Trading Halt
15/12/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
11/12/15
EVE Appendix 3B
30/11/15
EVE Change of Company Name
23/11/15
EVE Results of Meeting
20/11/15
EVE Net Tangible Asset Backing
13/11/15
EVE Appendix 4C - Quarterly
20/10/15PRICE SENSITIVE
EVE Notice of Annual General Meeting/Proxy Form
19/10/15
EVE Prospectus
19/10/15PRICE SENSITIVE
EVE Appendix 4G and Corporate Governance Statement
19/10/15
EVE Annual Report to shareholders
19/10/15
EVE Net Tangible Asset Backing
15/10/15
EVE Appendix 3B and Change of Director's Interest Notice x 3
02/10/15
EVE Net Tangible Asset Backing
14/09/15
EVE Change to AUD Presentation Currency
04/09/15
EVE Appendix 4E and Full Year Statutory Accounts
28/08/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
14/08/15
EVE Appendix 4C - Quarterly
30/07/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
13/07/15
EVE Change in Substantial Holding
09/07/15
EVE Change of Director's Interest Notice x 3
07/07/15
EVE Appendix 3B
07/07/15
EVE Placement
29/06/15PRICE SENSITIVE
EVE Trading Halt
25/06/15PRICE SENSITIVE
EVE Company Update
24/06/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
12/06/15
EVE Net Tangible Asset Backing
14/05/15
EVE Appendix 4C - Quarterly
27/04/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
14/04/15
EVE Change in substantial holding
10/04/15
EVE Change of Director's Interest Notice x 3
10/04/15
EVE Appendix 3B
10/04/15
EVE Net Tangible Asset Backing
12/03/15
EVE Half Yearly Report and Accounts
27/02/15PRICE SENSITIVE
EVE Company Update
27/02/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
10/02/15
EVE Appendix 4C - Quarterly
28/01/15PRICE SENSITIVE
EVE Net Tangible Asset Backing
13/01/15
EVE Change of Director's Interest Notice x 3
13/01/15
EVE Appendix 3B
13/01/15
EVE Net Tangible Asset Backing
10/12/14
EVE Results of Meeting
18/11/14
EVE Net Tangible Asset Backing
12/11/14
EVE Appendix 4C - Quarterly
30/10/14PRICE SENSITIVE
EVE Annual Report to shareholders
17/10/14
EVE Notice of General Meeting/Proxy Form
17/10/14
EVE Net Tangible Asset Backing
10/10/14
EVE Change of Director's Interest Notice x 3
01/10/14
EVE Appendix 3B
01/10/14
EVE Net Tangible Asset Backing
16/09/14
EVE Appendix 3B
02/09/14
EVE Appendix 4E and Full Year Statutory Accounts
29/08/14PRICE SENSITIVE
EVE Change of Company Address
22/08/14
EVE Net Tangible Asset Backing
13/08/14
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.1¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.274M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
EVE (ASX) Chart

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Tambourah chases gold veins and mineralisation extension with drilling Tambourah Metals Ltd has discovered two high-grade gold veins through a diamond drilling program in Western Australia
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.